Sun Pharma and Merck sign exclusive worldwide licensing agreement for Tildrakizumab
Tildrakizumab is a humanized, anti-IL-23p19 monoclonal antibody that binds specifically to IL-23p19 and is designed to selectively block the cytokine IL-23. It is currently being evaluated in Phase
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.